Manufacturing. Subject to the terms and conditions of this Agreement (including Section 5.3 and Annex 2) and the Manufacturing and Supply Agreement, Bioeq shall have the sole responsibility for the Manufacturing and supply of the Licensed Products to Licensee for Commercialization in the Field in the Territory.

Manufacturing. Upon EISAI’s request, [[EPIZYME:Organization]] shall, as part of the transition plan to be mutually agreed by the Parties under clause (e) below, at EISAI’s expense, transfer to EISAI (or its designee) any processes, documents, materials and other Know-How, to the extent the foregoing is Controlled by [[EPIZYME:Organization]] as of the effective date of termination and used in the Manufacture of Licensed Products in the Field as they exist as of the date of termination; provided that, upon EISAI’s request and pursuant to a supply agreement to be negotiated in good faith by the Parties, at a purchase price equal to [[EPIZYME:Organization]]’s Cost of Goods for clinical supplies and ​ of [[EPIZYME:Organization]]’s Cost of Goods for commercial supplies, supply EISAI with clinical and commercial quantities of the Licensed Products for the [[EPIZYME:Organization]] Territory in the dosage strengths, formulations and presentations under Development or being Commercialized by [[EPIZYME:Organization]], in either case, as of the effective date of termination, until the earlier of: # ​ months after the effective date of termination; or # establishment by EISAI of an alternative supply for such Licensed Products on commercially reasonable terms.

Manufacturing. Subject to the terms of this Agreement, Acceleron will have sole and exclusive control over all matters relating to manufacture and supply of Collaboration Molecules and Products, itself or through one or more Affiliates or Third Parties selected by Acceleron in its sole discretion.

Manufacturing. Vertex will have the exclusive right to Manufacture and supply Products either itself or through one or more Affiliates or Third Parties selected by Vertex in its sole discretion. The Parties may share information relating to the Manufacture of Products, and other products to be commercialized by CRISPR, to determine whether and how to leverage their respective manufacturing efforts, but shall have no obligation hereunder to enter into an agreement with respect thereto.

Manufacturing. During the Term, [[FibroGen:Organization]] will have the exclusive right to Manufacture and supply the Licensed Compounds and Licensed Products itself or through one or more Affiliates or [[FibroGen:Organization]] CMOs for Exploitation in the Field in the Territory.

Manufacturing. Evoke will Manufacture or have Manufactured Product by suppliers of its choice.

Manufacturing. To the extent vTv licenses the vTv Intellectual Property for any territory outside the Territory to a Third Party, vTv agrees that it will identify Huadong to such Third Party as a preferred manufacturing partner for the Manufacture of any Product; provided, however, that Huadong acknowledges that vTv has no control over the ultimate decisions of any potential Third Party licensee in its selection of a Manufacturer for Manufacturing outside of the Territory; provided, further, that Huadong shall offer a commercially reasonable manufacturing price for any such Third Party. vTv shall provide a written notice to Huadong with respect to any such license granted in accordance with this [Section 2.7] within ​ days after the execution of such license agreement.

Manufacturing. Allogene will have the exclusive right (subject to [Sections 2.2.4 and 4.5]) to Manufacture Allogene Licensed Products Targeting such Allogene Target itself or through one or more Affiliates or Third Parties selected by Allogene. Allogene will have no diligence obligations with respect to the Manufacture of Allogene Licensed Products except to the extent necessary to fulfill the Allogene Diligence Obligations. Allogene will be responsible for 100% of the associated costs for the manufacturing of Allogene Licensed Products.

Manufacturing. Upon [[EPIZYME:Organization]]’s request, EISAI shall, as part of the transition plan to be mutually agreed by the Parties under [clause (c) above], at [[EPIZYME:Organization]]’s expense, transfer to [[EPIZYME:Organization]] (or its designee) any processes, documents, materials and other Know-How, to the extent the foregoing is Controlled by EISAI as of the effective date of termination and used in the Manufacture of Licensed Products in the Field as they exist as of the date of termination.

Manufacturing. Subject to the terms and conditions of this Agreement, # Nurix, at its sole cost and expense, will Manufacture, itself or through Third Parties, Research supplies (other than GLP tox supplies) for the Parties’ use of the respective CTMs, Target Binders and Development Candidates in the Field in the Territory under the Collaboration, provided that ​, provided, further, that Research supplies for Sanofi shall be limited to those specified in any Research Plan for Sanofi activities or otherwise as permitted under [Section 2.7.4] (Activities to be Performed by Sanofi), and # Sanofi will have the sole and exclusive right to Manufacture (and will solely and exclusively control, at its discretion, the Manufacture of), itself or with or through its Affiliates, Sublicensees or other Third Parties, the GLP tox supplies, and supplies to support Development or Commercial activities for the respective Development Candidates, backups thereto and Licensed Products in the Field in the Territory. Subject to the Co-Development/Co-Commercialization Agreement and Profit/Loss Share Agreement (if executed), all such Manufacturing described in clause (b) will be at Sanofi’s sole cost and expense. Notwithstanding the foregoing, Sanofi shall have the right, but not the obligation, to Manufacture, itself or through Third Parties, Research supplies of ​ to enable Sanofi’s activities with respect to the Research of Collaboration ​, as assigned to Sanofi under the ​. Upon request, Nurix shall provide Sanofi with ​ for Sanofi to be able to Manufacture such Research supplies, including, without limitation, ​ for the relevant